Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 27;14(15):3653.
doi: 10.3390/cancers14153653.

Advances in Cutaneous Squamous Cell Carcinoma Management

Carrick Burns  1 , Shelby Kubicki  1 , Quoc-Bao Nguyen  1 , Nader Aboul-Fettouh  1 , Kelly M Wilmas  1 , Olivia M Chen  1 , Hung Quoc Doan  1 , Sirunya Silapunt  2 , Michael R Migden  3
Affiliations
Review

Advances in Cutaneous Squamous Cell Carcinoma Management

Carrick Burns et al. Cancers (Basel). .

Abstract

cSCC is increasing in prevalence due to increased lifespans and improvements in survival for conditions that increase the risk of cSCC. The absolute mortality of cSCC exceeds melanoma in the United States and approaches that of melanoma worldwide. This review presents significant changes in the management of cSCC, focusing on improvements in risk stratification, new treatment options, optimization of existing treatments, and prevention strategies. One major breakthrough in cSCC treatment is the advent of immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), which have ushered in a renaissance in the treatment of patients with locally advanced and metastatic disease. These agents have offered patients with advanced disease decreased therapeutic toxicity compared to traditional chemotherapy agents, a more durable response after discontinuation, and improved survival. cSCC is an active field of research, and this review will highlight some of the novel and more developed clinical trials that are likely to impact cSCC management in the near future.

Keywords: chemoprevention; cutaneous squamous cell carcinoma; immunotherapy; solid organ transplant recipients.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tokez S., Wakkee M., Kan W., Venables Z.C., Mooyaart A.L., Louwman M., Nijsten T., Hollestein L.M. Cumulative incidence and disease-specific survival of metastatic cutaneous squamous cell carcinoma: A nationwide cancer registry study. J. Am. Acad. Dermatol. 2022;86:331–338. doi: 10.1016/j.jaad.2021.09.067. - DOI - PubMed
    1. Brantsch K.D., Meisner C., Schönfisch B., Trilling B., Wehner-Caroli J., Röcken M., Breuninger H. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: A prospective study. Lancet Oncol. 2008;9:713–720. doi: 10.1016/S1470-2045(08)70178-5. - DOI - PubMed
    1. Edge S.B. AJCC Cancer Staging Manual. 7th ed. Springer; New York, NY, USA: 2010. American Joint Committee on Cancer.
    1. Hortlund M., Arroyo Mühr L.S., Storm H., Engholm G., Dillner J., Bzhalava D. Cancer risks after solid organ transplantation and after long-term dialysis. Int. J. Cancer. 2017;140:1091–1101. doi: 10.1002/ijc.30531. - DOI - PubMed
    1. Manyam B.V., Garsa A.A., Chin R.-I., Reddy C.A., Gastman B., Thorstad W., Yom S.S., Nussenbaum B., Wang S.J., Vidimos A.T., et al. A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck. Cancer. 2017;123:2054–2060. doi: 10.1002/cncr.30601. - DOI - PubMed